nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxybutynin—CYP3A4—bone cancer	0.794	1	CbGaD
Oxybutynin—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.00051	0.0186	CbGpPWpGaD
Oxybutynin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000491	0.0179	CbGpPWpGaD
Oxybutynin—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.00049	0.0179	CbGpPWpGaD
Oxybutynin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000462	0.0168	CbGpPWpGaD
Oxybutynin—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000455	0.0166	CbGpPWpGaD
Oxybutynin—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000442	0.0161	CbGpPWpGaD
Oxybutynin—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000433	0.0158	CbGpPWpGaD
Oxybutynin—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000425	0.0155	CbGpPWpGaD
Oxybutynin—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000394	0.0144	CbGpPWpGaD
Oxybutynin—Breast disorder—Doxorubicin—bone cancer	0.000389	0.00218	CcSEcCtD
Oxybutynin—Decreased appetite—Cisplatin—bone cancer	0.000387	0.00217	CcSEcCtD
Oxybutynin—Bronchitis—Epirubicin—bone cancer	0.000387	0.00217	CcSEcCtD
Oxybutynin—Nasopharyngitis—Doxorubicin—bone cancer	0.000385	0.00216	CcSEcCtD
Oxybutynin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000384	0.00216	CcSEcCtD
Oxybutynin—Infestation—Methotrexate—bone cancer	0.000383	0.00215	CcSEcCtD
Oxybutynin—Infestation NOS—Methotrexate—bone cancer	0.000383	0.00215	CcSEcCtD
Oxybutynin—Drowsiness—Methotrexate—bone cancer	0.000383	0.00215	CcSEcCtD
Oxybutynin—Depression—Methotrexate—bone cancer	0.000382	0.00214	CcSEcCtD
Oxybutynin—Pain—Cisplatin—bone cancer	0.000381	0.00213	CcSEcCtD
Oxybutynin—Dysuria—Epirubicin—bone cancer	0.000376	0.00211	CcSEcCtD
Oxybutynin—Abdominal distension—Doxorubicin—bone cancer	0.000375	0.0021	CcSEcCtD
Oxybutynin—Upper respiratory tract infection—Epirubicin—bone cancer	0.000374	0.0021	CcSEcCtD
Oxybutynin—Stomatitis—Methotrexate—bone cancer	0.000373	0.00209	CcSEcCtD
Oxybutynin—Conjunctivitis—Methotrexate—bone cancer	0.000372	0.00209	CcSEcCtD
Oxybutynin—Dysphagia—Doxorubicin—bone cancer	0.000372	0.00209	CcSEcCtD
Oxybutynin—Asthma—Doxorubicin—bone cancer	0.000372	0.00209	CcSEcCtD
Oxybutynin—Influenza—Doxorubicin—bone cancer	0.000372	0.00209	CcSEcCtD
Oxybutynin—Pollakiuria—Epirubicin—bone cancer	0.000371	0.00208	CcSEcCtD
Oxybutynin—Feeling abnormal—Cisplatin—bone cancer	0.000367	0.00206	CcSEcCtD
Oxybutynin—Haematuria—Methotrexate—bone cancer	0.000365	0.00205	CcSEcCtD
Oxybutynin—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000363	0.0132	CbGpPWpGaD
Oxybutynin—Epistaxis—Methotrexate—bone cancer	0.000361	0.00203	CcSEcCtD
Oxybutynin—Drowsiness—Epirubicin—bone cancer	0.000359	0.00201	CcSEcCtD
Oxybutynin—Infestation—Epirubicin—bone cancer	0.000359	0.00201	CcSEcCtD
Oxybutynin—Infestation NOS—Epirubicin—bone cancer	0.000359	0.00201	CcSEcCtD
Oxybutynin—Bronchitis—Doxorubicin—bone cancer	0.000358	0.00201	CcSEcCtD
Oxybutynin—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00035	0.0128	CbGpPWpGaD
Oxybutynin—Stomatitis—Epirubicin—bone cancer	0.000349	0.00196	CcSEcCtD
Oxybutynin—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000349	0.0127	CbGpPWpGaD
Oxybutynin—Conjunctivitis—Epirubicin—bone cancer	0.000348	0.00195	CcSEcCtD
Oxybutynin—Urinary tract infection—Epirubicin—bone cancer	0.000348	0.00195	CcSEcCtD
Oxybutynin—Dysuria—Doxorubicin—bone cancer	0.000348	0.00195	CcSEcCtD
Oxybutynin—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000346	0.00194	CcSEcCtD
Oxybutynin—Pollakiuria—Doxorubicin—bone cancer	0.000344	0.00193	CcSEcCtD
Oxybutynin—CHRM5—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000342	0.0125	CbGpPWpGaD
Oxybutynin—Haematuria—Epirubicin—bone cancer	0.000342	0.00192	CcSEcCtD
Oxybutynin—Pharyngitis—Methotrexate—bone cancer	0.000341	0.00191	CcSEcCtD
Oxybutynin—Urinary tract disorder—Methotrexate—bone cancer	0.00034	0.0019	CcSEcCtD
Oxybutynin—Epistaxis—Epirubicin—bone cancer	0.000338	0.0019	CcSEcCtD
Oxybutynin—Urethral disorder—Methotrexate—bone cancer	0.000337	0.00189	CcSEcCtD
Oxybutynin—Sinusitis—Epirubicin—bone cancer	0.000336	0.00189	CcSEcCtD
Oxybutynin—Infestation—Doxorubicin—bone cancer	0.000332	0.00186	CcSEcCtD
Oxybutynin—Infestation NOS—Doxorubicin—bone cancer	0.000332	0.00186	CcSEcCtD
Oxybutynin—Drowsiness—Doxorubicin—bone cancer	0.000332	0.00186	CcSEcCtD
Oxybutynin—Visual impairment—Methotrexate—bone cancer	0.000331	0.00186	CcSEcCtD
Oxybutynin—Hypersensitivity—Cisplatin—bone cancer	0.000328	0.00184	CcSEcCtD
Oxybutynin—Stomatitis—Doxorubicin—bone cancer	0.000323	0.00181	CcSEcCtD
Oxybutynin—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000323	0.0118	CbGpPWpGaD
Oxybutynin—Rhinitis—Epirubicin—bone cancer	0.000323	0.00181	CcSEcCtD
Oxybutynin—Conjunctivitis—Doxorubicin—bone cancer	0.000322	0.00181	CcSEcCtD
Oxybutynin—Urinary tract infection—Doxorubicin—bone cancer	0.000322	0.00181	CcSEcCtD
Oxybutynin—Eye disorder—Methotrexate—bone cancer	0.000321	0.0018	CcSEcCtD
Oxybutynin—Tinnitus—Methotrexate—bone cancer	0.000321	0.0018	CcSEcCtD
Oxybutynin—Hypoaesthesia—Epirubicin—bone cancer	0.00032	0.0018	CcSEcCtD
Oxybutynin—Asthenia—Cisplatin—bone cancer	0.000319	0.00179	CcSEcCtD
Oxybutynin—Pharyngitis—Epirubicin—bone cancer	0.000319	0.00179	CcSEcCtD
Oxybutynin—Cardiac disorder—Methotrexate—bone cancer	0.000319	0.00179	CcSEcCtD
Oxybutynin—Urinary tract disorder—Epirubicin—bone cancer	0.000318	0.00178	CcSEcCtD
Oxybutynin—Oedema peripheral—Epirubicin—bone cancer	0.000317	0.00178	CcSEcCtD
Oxybutynin—Haematuria—Doxorubicin—bone cancer	0.000316	0.00177	CcSEcCtD
Oxybutynin—Connective tissue disorder—Epirubicin—bone cancer	0.000316	0.00177	CcSEcCtD
Oxybutynin—Urethral disorder—Epirubicin—bone cancer	0.000315	0.00177	CcSEcCtD
Oxybutynin—Epistaxis—Doxorubicin—bone cancer	0.000313	0.00175	CcSEcCtD
Oxybutynin—CHRM1—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000313	0.0114	CbGpPWpGaD
Oxybutynin—Angiopathy—Methotrexate—bone cancer	0.000312	0.00175	CcSEcCtD
Oxybutynin—Sinusitis—Doxorubicin—bone cancer	0.000311	0.00174	CcSEcCtD
Oxybutynin—Visual impairment—Epirubicin—bone cancer	0.00031	0.00174	CcSEcCtD
Oxybutynin—Mediastinal disorder—Methotrexate—bone cancer	0.00031	0.00174	CcSEcCtD
Oxybutynin—CHRM3—GPCRs, Other—GRM1—bone cancer	0.000309	0.0113	CbGpPWpGaD
Oxybutynin—CHRM2—GPCRs, Other—GRM1—bone cancer	0.000306	0.0112	CbGpPWpGaD
Oxybutynin—Diarrhoea—Cisplatin—bone cancer	0.000305	0.00171	CcSEcCtD
Oxybutynin—Mental disorder—Methotrexate—bone cancer	0.000301	0.00169	CcSEcCtD
Oxybutynin—Eye disorder—Epirubicin—bone cancer	0.000301	0.00169	CcSEcCtD
Oxybutynin—Tinnitus—Epirubicin—bone cancer	0.0003	0.00168	CcSEcCtD
Oxybutynin—Malnutrition—Methotrexate—bone cancer	0.000299	0.00168	CcSEcCtD
Oxybutynin—Erythema—Methotrexate—bone cancer	0.000299	0.00168	CcSEcCtD
Oxybutynin—Cardiac disorder—Epirubicin—bone cancer	0.000299	0.00167	CcSEcCtD
Oxybutynin—Flushing—Epirubicin—bone cancer	0.000299	0.00167	CcSEcCtD
Oxybutynin—Rhinitis—Doxorubicin—bone cancer	0.000299	0.00167	CcSEcCtD
Oxybutynin—Hypoaesthesia—Doxorubicin—bone cancer	0.000296	0.00166	CcSEcCtD
Oxybutynin—Pharyngitis—Doxorubicin—bone cancer	0.000296	0.00166	CcSEcCtD
Oxybutynin—Urinary tract disorder—Doxorubicin—bone cancer	0.000294	0.00165	CcSEcCtD
Oxybutynin—Oedema peripheral—Doxorubicin—bone cancer	0.000293	0.00164	CcSEcCtD
Oxybutynin—Dysgeusia—Methotrexate—bone cancer	0.000293	0.00164	CcSEcCtD
Oxybutynin—Connective tissue disorder—Doxorubicin—bone cancer	0.000293	0.00164	CcSEcCtD
Oxybutynin—Angiopathy—Epirubicin—bone cancer	0.000292	0.00164	CcSEcCtD
Oxybutynin—Urethral disorder—Doxorubicin—bone cancer	0.000292	0.00164	CcSEcCtD
Oxybutynin—Mediastinal disorder—Epirubicin—bone cancer	0.00029	0.00163	CcSEcCtD
Oxybutynin—Back pain—Methotrexate—bone cancer	0.00029	0.00162	CcSEcCtD
Oxybutynin—Arrhythmia—Epirubicin—bone cancer	0.000288	0.00161	CcSEcCtD
Oxybutynin—Visual impairment—Doxorubicin—bone cancer	0.000287	0.00161	CcSEcCtD
Oxybutynin—Vomiting—Cisplatin—bone cancer	0.000283	0.00159	CcSEcCtD
Oxybutynin—Vision blurred—Methotrexate—bone cancer	0.000282	0.00158	CcSEcCtD
Oxybutynin—Mental disorder—Epirubicin—bone cancer	0.000282	0.00158	CcSEcCtD
Oxybutynin—Rash—Cisplatin—bone cancer	0.000281	0.00157	CcSEcCtD
Oxybutynin—Dermatitis—Cisplatin—bone cancer	0.00028	0.00157	CcSEcCtD
Oxybutynin—Erythema—Epirubicin—bone cancer	0.00028	0.00157	CcSEcCtD
Oxybutynin—Malnutrition—Epirubicin—bone cancer	0.00028	0.00157	CcSEcCtD
Oxybutynin—Eye disorder—Doxorubicin—bone cancer	0.000278	0.00156	CcSEcCtD
Oxybutynin—Ill-defined disorder—Methotrexate—bone cancer	0.000278	0.00156	CcSEcCtD
Oxybutynin—Tinnitus—Doxorubicin—bone cancer	0.000278	0.00156	CcSEcCtD
Oxybutynin—Flushing—Doxorubicin—bone cancer	0.000276	0.00155	CcSEcCtD
Oxybutynin—Cardiac disorder—Doxorubicin—bone cancer	0.000276	0.00155	CcSEcCtD
Oxybutynin—Flatulence—Epirubicin—bone cancer	0.000276	0.00155	CcSEcCtD
Oxybutynin—Tension—Epirubicin—bone cancer	0.000275	0.00154	CcSEcCtD
Oxybutynin—Dysgeusia—Epirubicin—bone cancer	0.000274	0.00154	CcSEcCtD
Oxybutynin—Nervousness—Epirubicin—bone cancer	0.000272	0.00153	CcSEcCtD
Oxybutynin—Back pain—Epirubicin—bone cancer	0.000271	0.00152	CcSEcCtD
Oxybutynin—Angiopathy—Doxorubicin—bone cancer	0.00027	0.00151	CcSEcCtD
Oxybutynin—Malaise—Methotrexate—bone cancer	0.00027	0.00151	CcSEcCtD
Oxybutynin—Mediastinal disorder—Doxorubicin—bone cancer	0.000268	0.0015	CcSEcCtD
Oxybutynin—Arrhythmia—Doxorubicin—bone cancer	0.000266	0.00149	CcSEcCtD
Oxybutynin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000265	0.00968	CbGpPWpGaD
Oxybutynin—Nausea—Cisplatin—bone cancer	0.000264	0.00148	CcSEcCtD
Oxybutynin—Vision blurred—Epirubicin—bone cancer	0.000264	0.00148	CcSEcCtD
Oxybutynin—Cough—Methotrexate—bone cancer	0.000261	0.00146	CcSEcCtD
Oxybutynin—Mental disorder—Doxorubicin—bone cancer	0.000261	0.00146	CcSEcCtD
Oxybutynin—Ill-defined disorder—Epirubicin—bone cancer	0.00026	0.00146	CcSEcCtD
Oxybutynin—Convulsion—Methotrexate—bone cancer	0.000259	0.00145	CcSEcCtD
Oxybutynin—Erythema—Doxorubicin—bone cancer	0.000259	0.00145	CcSEcCtD
Oxybutynin—Malnutrition—Doxorubicin—bone cancer	0.000259	0.00145	CcSEcCtD
Oxybutynin—Agitation—Epirubicin—bone cancer	0.000257	0.00144	CcSEcCtD
Oxybutynin—Flatulence—Doxorubicin—bone cancer	0.000255	0.00143	CcSEcCtD
Oxybutynin—Chest pain—Methotrexate—bone cancer	0.000255	0.00143	CcSEcCtD
Oxybutynin—Arthralgia—Methotrexate—bone cancer	0.000255	0.00143	CcSEcCtD
Oxybutynin—Tension—Doxorubicin—bone cancer	0.000254	0.00143	CcSEcCtD
Oxybutynin—Dysgeusia—Doxorubicin—bone cancer	0.000254	0.00142	CcSEcCtD
Oxybutynin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000253	0.00142	CcSEcCtD
Oxybutynin—Malaise—Epirubicin—bone cancer	0.000253	0.00142	CcSEcCtD
Oxybutynin—Discomfort—Methotrexate—bone cancer	0.000252	0.00141	CcSEcCtD
Oxybutynin—Nervousness—Doxorubicin—bone cancer	0.000252	0.00141	CcSEcCtD
Oxybutynin—Syncope—Epirubicin—bone cancer	0.000251	0.00141	CcSEcCtD
Oxybutynin—Back pain—Doxorubicin—bone cancer	0.000251	0.00141	CcSEcCtD
Oxybutynin—Palpitations—Epirubicin—bone cancer	0.000248	0.00139	CcSEcCtD
Oxybutynin—CHRM5—G alpha (q) signalling events—GRM1—bone cancer	0.000247	0.00902	CbGpPWpGaD
Oxybutynin—Confusional state—Methotrexate—bone cancer	0.000246	0.00138	CcSEcCtD
Oxybutynin—Loss of consciousness—Epirubicin—bone cancer	0.000246	0.00138	CcSEcCtD
Oxybutynin—Cough—Epirubicin—bone cancer	0.000244	0.00137	CcSEcCtD
Oxybutynin—Anaphylactic shock—Methotrexate—bone cancer	0.000244	0.00137	CcSEcCtD
Oxybutynin—Vision blurred—Doxorubicin—bone cancer	0.000244	0.00137	CcSEcCtD
Oxybutynin—Convulsion—Epirubicin—bone cancer	0.000243	0.00136	CcSEcCtD
Oxybutynin—Infection—Methotrexate—bone cancer	0.000243	0.00136	CcSEcCtD
Oxybutynin—Hypertension—Epirubicin—bone cancer	0.000242	0.00136	CcSEcCtD
Oxybutynin—CHRM1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000241	0.00878	CbGpPWpGaD
Oxybutynin—Ill-defined disorder—Doxorubicin—bone cancer	0.000241	0.00135	CcSEcCtD
Oxybutynin—CHRM3—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00024	0.00875	CbGpPWpGaD
Oxybutynin—Nervous system disorder—Methotrexate—bone cancer	0.00024	0.00134	CcSEcCtD
Oxybutynin—Chest pain—Epirubicin—bone cancer	0.000239	0.00134	CcSEcCtD
Oxybutynin—Arthralgia—Epirubicin—bone cancer	0.000239	0.00134	CcSEcCtD
Oxybutynin—Agitation—Doxorubicin—bone cancer	0.000238	0.00134	CcSEcCtD
Oxybutynin—CHRM2—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000238	0.00867	CbGpPWpGaD
Oxybutynin—Anxiety—Epirubicin—bone cancer	0.000238	0.00133	CcSEcCtD
Oxybutynin—Skin disorder—Methotrexate—bone cancer	0.000237	0.00133	CcSEcCtD
Oxybutynin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000237	0.00133	CcSEcCtD
Oxybutynin—Discomfort—Epirubicin—bone cancer	0.000236	0.00132	CcSEcCtD
Oxybutynin—Malaise—Doxorubicin—bone cancer	0.000234	0.00131	CcSEcCtD
Oxybutynin—Dry mouth—Epirubicin—bone cancer	0.000233	0.00131	CcSEcCtD
Oxybutynin—Anorexia—Methotrexate—bone cancer	0.000233	0.00131	CcSEcCtD
Oxybutynin—Syncope—Doxorubicin—bone cancer	0.000232	0.0013	CcSEcCtD
Oxybutynin—Confusional state—Epirubicin—bone cancer	0.000231	0.00129	CcSEcCtD
Oxybutynin—Palpitations—Doxorubicin—bone cancer	0.000229	0.00128	CcSEcCtD
Oxybutynin—Oedema—Epirubicin—bone cancer	0.000229	0.00128	CcSEcCtD
Oxybutynin—Anaphylactic shock—Epirubicin—bone cancer	0.000229	0.00128	CcSEcCtD
Oxybutynin—Hypotension—Methotrexate—bone cancer	0.000228	0.00128	CcSEcCtD
Oxybutynin—Loss of consciousness—Doxorubicin—bone cancer	0.000228	0.00128	CcSEcCtD
Oxybutynin—CHRM3—Regulation of insulin secretion—GNA11—bone cancer	0.000227	0.00829	CbGpPWpGaD
Oxybutynin—Infection—Epirubicin—bone cancer	0.000227	0.00127	CcSEcCtD
Oxybutynin—Cough—Doxorubicin—bone cancer	0.000226	0.00127	CcSEcCtD
Oxybutynin—Shock—Epirubicin—bone cancer	0.000225	0.00126	CcSEcCtD
Oxybutynin—Convulsion—Doxorubicin—bone cancer	0.000225	0.00126	CcSEcCtD
Oxybutynin—Nervous system disorder—Epirubicin—bone cancer	0.000224	0.00126	CcSEcCtD
Oxybutynin—Hypertension—Doxorubicin—bone cancer	0.000224	0.00125	CcSEcCtD
Oxybutynin—Tachycardia—Epirubicin—bone cancer	0.000223	0.00125	CcSEcCtD
Oxybutynin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000223	0.00125	CcSEcCtD
Oxybutynin—Skin disorder—Epirubicin—bone cancer	0.000222	0.00125	CcSEcCtD
Oxybutynin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000221	0.00807	CbGpPWpGaD
Oxybutynin—Insomnia—Methotrexate—bone cancer	0.000221	0.00124	CcSEcCtD
Oxybutynin—Arthralgia—Doxorubicin—bone cancer	0.000221	0.00124	CcSEcCtD
Oxybutynin—Chest pain—Doxorubicin—bone cancer	0.000221	0.00124	CcSEcCtD
Oxybutynin—Anxiety—Doxorubicin—bone cancer	0.00022	0.00123	CcSEcCtD
Oxybutynin—Paraesthesia—Methotrexate—bone cancer	0.000219	0.00123	CcSEcCtD
Oxybutynin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000219	0.00123	CcSEcCtD
Oxybutynin—Discomfort—Doxorubicin—bone cancer	0.000218	0.00122	CcSEcCtD
Oxybutynin—Anorexia—Epirubicin—bone cancer	0.000218	0.00122	CcSEcCtD
Oxybutynin—CHRM3—GPCRs, Other—SMO—bone cancer	0.000218	0.00793	CbGpPWpGaD
Oxybutynin—Somnolence—Methotrexate—bone cancer	0.000217	0.00122	CcSEcCtD
Oxybutynin—Dry mouth—Doxorubicin—bone cancer	0.000216	0.00121	CcSEcCtD
Oxybutynin—CHRM2—GPCRs, Other—SMO—bone cancer	0.000215	0.00786	CbGpPWpGaD
Oxybutynin—Dyspepsia—Methotrexate—bone cancer	0.000215	0.00121	CcSEcCtD
Oxybutynin—Hypotension—Epirubicin—bone cancer	0.000214	0.0012	CcSEcCtD
Oxybutynin—Confusional state—Doxorubicin—bone cancer	0.000213	0.0012	CcSEcCtD
Oxybutynin—Decreased appetite—Methotrexate—bone cancer	0.000212	0.00119	CcSEcCtD
Oxybutynin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000212	0.00772	CbGpPWpGaD
Oxybutynin—Oedema—Doxorubicin—bone cancer	0.000212	0.00119	CcSEcCtD
Oxybutynin—Anaphylactic shock—Doxorubicin—bone cancer	0.000212	0.00119	CcSEcCtD
Oxybutynin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000211	0.00771	CbGpPWpGaD
Oxybutynin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000211	0.00118	CcSEcCtD
Oxybutynin—Fatigue—Methotrexate—bone cancer	0.000211	0.00118	CcSEcCtD
Oxybutynin—Infection—Doxorubicin—bone cancer	0.00021	0.00118	CcSEcCtD
Oxybutynin—Pain—Methotrexate—bone cancer	0.000209	0.00117	CcSEcCtD
Oxybutynin—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000209	0.00762	CbGpPWpGaD
Oxybutynin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000208	0.00117	CcSEcCtD
Oxybutynin—Shock—Doxorubicin—bone cancer	0.000208	0.00117	CcSEcCtD
Oxybutynin—Nervous system disorder—Doxorubicin—bone cancer	0.000207	0.00116	CcSEcCtD
Oxybutynin—Insomnia—Epirubicin—bone cancer	0.000207	0.00116	CcSEcCtD
Oxybutynin—Tachycardia—Doxorubicin—bone cancer	0.000206	0.00116	CcSEcCtD
Oxybutynin—Skin disorder—Doxorubicin—bone cancer	0.000205	0.00115	CcSEcCtD
Oxybutynin—Paraesthesia—Epirubicin—bone cancer	0.000205	0.00115	CcSEcCtD
Oxybutynin—Somnolence—Epirubicin—bone cancer	0.000203	0.00114	CcSEcCtD
Oxybutynin—Anorexia—Doxorubicin—bone cancer	0.000202	0.00113	CcSEcCtD
Oxybutynin—Feeling abnormal—Methotrexate—bone cancer	0.000201	0.00113	CcSEcCtD
Oxybutynin—Dyspepsia—Epirubicin—bone cancer	0.000201	0.00113	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Methotrexate—bone cancer	0.0002	0.00112	CcSEcCtD
Oxybutynin—Decreased appetite—Epirubicin—bone cancer	0.000199	0.00111	CcSEcCtD
Oxybutynin—Hypotension—Doxorubicin—bone cancer	0.000198	0.00111	CcSEcCtD
Oxybutynin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000197	0.00111	CcSEcCtD
Oxybutynin—Fatigue—Epirubicin—bone cancer	0.000197	0.00111	CcSEcCtD
Oxybutynin—Pain—Epirubicin—bone cancer	0.000196	0.0011	CcSEcCtD
Oxybutynin—Constipation—Epirubicin—bone cancer	0.000196	0.0011	CcSEcCtD
Oxybutynin—Urticaria—Methotrexate—bone cancer	0.000194	0.00109	CcSEcCtD
Oxybutynin—Abdominal pain—Methotrexate—bone cancer	0.000193	0.00108	CcSEcCtD
Oxybutynin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000193	0.00108	CcSEcCtD
Oxybutynin—Insomnia—Doxorubicin—bone cancer	0.000191	0.00107	CcSEcCtD
Oxybutynin—CHRM5—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000191	0.00697	CbGpPWpGaD
Oxybutynin—Paraesthesia—Doxorubicin—bone cancer	0.00019	0.00107	CcSEcCtD
Oxybutynin—Feeling abnormal—Epirubicin—bone cancer	0.000188	0.00106	CcSEcCtD
Oxybutynin—Somnolence—Doxorubicin—bone cancer	0.000188	0.00105	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Epirubicin—bone cancer	0.000187	0.00105	CcSEcCtD
Oxybutynin—Dyspepsia—Doxorubicin—bone cancer	0.000186	0.00104	CcSEcCtD
Oxybutynin—Decreased appetite—Doxorubicin—bone cancer	0.000184	0.00103	CcSEcCtD
Oxybutynin—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000183	0.00669	CbGpPWpGaD
Oxybutynin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000183	0.00102	CcSEcCtD
Oxybutynin—Fatigue—Doxorubicin—bone cancer	0.000182	0.00102	CcSEcCtD
Oxybutynin—Urticaria—Epirubicin—bone cancer	0.000182	0.00102	CcSEcCtD
Oxybutynin—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000181	0.0066	CbGpPWpGaD
Oxybutynin—Constipation—Doxorubicin—bone cancer	0.000181	0.00101	CcSEcCtD
Oxybutynin—Pain—Doxorubicin—bone cancer	0.000181	0.00101	CcSEcCtD
Oxybutynin—Abdominal pain—Epirubicin—bone cancer	0.000181	0.00101	CcSEcCtD
Oxybutynin—Hypersensitivity—Methotrexate—bone cancer	0.00018	0.00101	CcSEcCtD
Oxybutynin—CHRM3—Integration of energy metabolism—GNA11—bone cancer	0.000179	0.00652	CbGpPWpGaD
Oxybutynin—Asthenia—Methotrexate—bone cancer	0.000175	0.000983	CcSEcCtD
Oxybutynin—Feeling abnormal—Doxorubicin—bone cancer	0.000174	0.000978	CcSEcCtD
Oxybutynin—CHRM1—G alpha (q) signalling events—GRM1—bone cancer	0.000174	0.00635	CbGpPWpGaD
Oxybutynin—CHRM3—G alpha (q) signalling events—GRM1—bone cancer	0.000174	0.00633	CbGpPWpGaD
Oxybutynin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000173	0.00097	CcSEcCtD
Oxybutynin—Pruritus—Methotrexate—bone cancer	0.000173	0.000969	CcSEcCtD
Oxybutynin—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000172	0.00626	CbGpPWpGaD
Oxybutynin—Hypersensitivity—Epirubicin—bone cancer	0.000168	0.000945	CcSEcCtD
Oxybutynin—Urticaria—Doxorubicin—bone cancer	0.000168	0.000942	CcSEcCtD
Oxybutynin—Abdominal pain—Doxorubicin—bone cancer	0.000167	0.000938	CcSEcCtD
Oxybutynin—Diarrhoea—Methotrexate—bone cancer	0.000167	0.000937	CcSEcCtD
Oxybutynin—CHRM2—G alpha (i) signalling events—GRM4—bone cancer	0.000165	0.00602	CbGpPWpGaD
Oxybutynin—CHRM2—G alpha (i) signalling events—RGS1—bone cancer	0.000165	0.00602	CbGpPWpGaD
Oxybutynin—Asthenia—Epirubicin—bone cancer	0.000164	0.00092	CcSEcCtD
Oxybutynin—Pruritus—Epirubicin—bone cancer	0.000162	0.000907	CcSEcCtD
Oxybutynin—Dizziness—Methotrexate—bone cancer	0.000162	0.000906	CcSEcCtD
Oxybutynin—CHRM5—G alpha (q) signalling events—GNA11—bone cancer	0.000159	0.00581	CbGpPWpGaD
Oxybutynin—Diarrhoea—Epirubicin—bone cancer	0.000156	0.000877	CcSEcCtD
Oxybutynin—Hypersensitivity—Doxorubicin—bone cancer	0.000156	0.000874	CcSEcCtD
Oxybutynin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000156	0.00568	CbGpPWpGaD
Oxybutynin—Vomiting—Methotrexate—bone cancer	0.000155	0.000871	CcSEcCtD
Oxybutynin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000155	0.00566	CbGpPWpGaD
Oxybutynin—Rash—Methotrexate—bone cancer	0.000154	0.000864	CcSEcCtD
Oxybutynin—Dermatitis—Methotrexate—bone cancer	0.000154	0.000863	CcSEcCtD
Oxybutynin—Headache—Methotrexate—bone cancer	0.000153	0.000858	CcSEcCtD
Oxybutynin—Asthenia—Doxorubicin—bone cancer	0.000152	0.000851	CcSEcCtD
Oxybutynin—Dizziness—Epirubicin—bone cancer	0.000151	0.000848	CcSEcCtD
Oxybutynin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000151	0.00549	CbGpPWpGaD
Oxybutynin—Pruritus—Doxorubicin—bone cancer	0.00015	0.000839	CcSEcCtD
Oxybutynin—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000149	0.00542	CbGpPWpGaD
Oxybutynin—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000149	0.00542	CbGpPWpGaD
Oxybutynin—Vomiting—Epirubicin—bone cancer	0.000145	0.000815	CcSEcCtD
Oxybutynin—Nausea—Methotrexate—bone cancer	0.000145	0.000814	CcSEcCtD
Oxybutynin—Diarrhoea—Doxorubicin—bone cancer	0.000145	0.000812	CcSEcCtD
Oxybutynin—Rash—Epirubicin—bone cancer	0.000144	0.000808	CcSEcCtD
Oxybutynin—Dermatitis—Epirubicin—bone cancer	0.000144	0.000808	CcSEcCtD
Oxybutynin—CHRM5—GPCR ligand binding—GRM4—bone cancer	0.000144	0.00525	CbGpPWpGaD
Oxybutynin—Headache—Epirubicin—bone cancer	0.000143	0.000803	CcSEcCtD
Oxybutynin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000143	0.0052	CbGpPWpGaD
Oxybutynin—Dizziness—Doxorubicin—bone cancer	0.00014	0.000784	CcSEcCtD
Oxybutynin—Nausea—Epirubicin—bone cancer	0.000136	0.000762	CcSEcCtD
Oxybutynin—CHRM1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000135	0.00491	CbGpPWpGaD
Oxybutynin—Vomiting—Doxorubicin—bone cancer	0.000135	0.000754	CcSEcCtD
Oxybutynin—CHRM3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000134	0.00489	CbGpPWpGaD
Oxybutynin—Rash—Doxorubicin—bone cancer	0.000133	0.000748	CcSEcCtD
Oxybutynin—Dermatitis—Doxorubicin—bone cancer	0.000133	0.000747	CcSEcCtD
Oxybutynin—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000133	0.00484	CbGpPWpGaD
Oxybutynin—Headache—Doxorubicin—bone cancer	0.000133	0.000743	CcSEcCtD
Oxybutynin—Nausea—Doxorubicin—bone cancer	0.000126	0.000705	CcSEcCtD
Oxybutynin—CHRM5—GPCR ligand binding—GRM1—bone cancer	0.000125	0.00455	CbGpPWpGaD
Oxybutynin—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000122	0.00445	CbGpPWpGaD
Oxybutynin—CHRM1—G alpha (q) signalling events—GNA11—bone cancer	0.000112	0.00409	CbGpPWpGaD
Oxybutynin—CHRM3—G alpha (q) signalling events—GNA11—bone cancer	0.000112	0.00408	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—GNA11—bone cancer	0.000106	0.00386	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—EZH2—bone cancer	0.000105	0.00384	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR ligand binding—GRM4—bone cancer	0.000101	0.00369	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR ligand binding—GRM4—bone cancer	0.000101	0.00368	CbGpPWpGaD
Oxybutynin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.0001	0.00366	CbGpPWpGaD
Oxybutynin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.0001	0.00365	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR ligand binding—GRM4—bone cancer	0.0001	0.00365	CbGpPWpGaD
Oxybutynin—CHRM5—Regulation of Actin Cytoskeleton—BRAF—bone cancer	9.5e-05	0.00347	CbGpPWpGaD
Oxybutynin—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	9.4e-05	0.00343	CbGpPWpGaD
Oxybutynin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	9.12e-05	0.00332	CbGpPWpGaD
Oxybutynin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	8.99e-05	0.00328	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR ligand binding—SMO—bone cancer	8.79e-05	0.0032	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR ligand binding—GRM1—bone cancer	8.78e-05	0.0032	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR ligand binding—GRM1—bone cancer	8.75e-05	0.00319	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR ligand binding—GRM1—bone cancer	8.67e-05	0.00316	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—RGS1—bone cancer	8.13e-05	0.00296	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—GRM4—bone cancer	8.13e-05	0.00296	CbGpPWpGaD
Oxybutynin—CYP2C8—Biological oxidations—CYP3A4—bone cancer	7.9e-05	0.00288	CbGpPWpGaD
Oxybutynin—CYP3A5—Biological oxidations—GSTP1—bone cancer	7.8e-05	0.00284	CbGpPWpGaD
Oxybutynin—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	7.79e-05	0.00284	CbGpPWpGaD
Oxybutynin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	7.69e-05	0.0028	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—GRM4—bone cancer	7.38e-05	0.00269	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—RGS1—bone cancer	7.38e-05	0.00269	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—GRM1—bone cancer	7.05e-05	0.00257	CbGpPWpGaD
Oxybutynin—CYP2C8—Biological oxidations—GSTP1—bone cancer	6.75e-05	0.00246	CbGpPWpGaD
Oxybutynin—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	6.69e-05	0.00244	CbGpPWpGaD
Oxybutynin—CHRM3—Regulation of Actin Cytoskeleton—BRAF—bone cancer	6.67e-05	0.00243	CbGpPWpGaD
Oxybutynin—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	6.66e-05	0.00243	CbGpPWpGaD
Oxybutynin—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	6.61e-05	0.00241	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—NDUFA12—bone cancer	6.5e-05	0.00237	CbGpPWpGaD
Oxybutynin—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.48e-05	0.00236	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—GRM1—bone cancer	6.4e-05	0.00233	CbGpPWpGaD
Oxybutynin—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.39e-05	0.00233	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR ligand binding—SMO—bone cancer	6.19e-05	0.00226	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR ligand binding—SMO—bone cancer	6.17e-05	0.00225	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR ligand binding—SMO—bone cancer	6.11e-05	0.00223	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—CDK4—bone cancer	5.95e-05	0.00217	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—GRM4—bone cancer	5.72e-05	0.00209	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—RGS1—bone cancer	5.72e-05	0.00209	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—GRM4—bone cancer	5.71e-05	0.00208	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—RGS1—bone cancer	5.71e-05	0.00208	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—RGS1—bone cancer	5.65e-05	0.00206	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—GRM4—bone cancer	5.65e-05	0.00206	CbGpPWpGaD
Oxybutynin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.59e-05	0.00204	CbGpPWpGaD
Oxybutynin—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.54e-05	0.00202	CbGpPWpGaD
Oxybutynin—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.47e-05	0.00199	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—NDUFA12—bone cancer	5.46e-05	0.00199	CbGpPWpGaD
Oxybutynin—CHRM5—Regulation of Actin Cytoskeleton—EGFR—bone cancer	5.44e-05	0.00198	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—NT5C3A—bone cancer	5.38e-05	0.00196	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—GRM4—bone cancer	5.2e-05	0.0019	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—RGS1—bone cancer	5.2e-05	0.0019	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—GRM4—bone cancer	5.18e-05	0.00189	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—RGS1—bone cancer	5.18e-05	0.00189	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—GRM4—bone cancer	5.13e-05	0.00187	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—RGS1—bone cancer	5.13e-05	0.00187	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—GRM1—bone cancer	4.96e-05	0.00181	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—GRM1—bone cancer	4.95e-05	0.0018	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—GRM1—bone cancer	4.9e-05	0.00179	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—NDUFA12—bone cancer	4.73e-05	0.00173	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	4.64e-05	0.00169	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—GNA11—bone cancer	4.54e-05	0.00166	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—NT5C3A—bone cancer	4.53e-05	0.00165	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—SMO—bone cancer	4.51e-05	0.00164	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—GRM1—bone cancer	4.51e-05	0.00164	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—GRM1—bone cancer	4.49e-05	0.00164	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—GRM1—bone cancer	4.45e-05	0.00162	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—RGS1—bone cancer	4.36e-05	0.00159	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—GRM4—bone cancer	4.36e-05	0.00159	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—GNA11—bone cancer	4.12e-05	0.0015	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—IL3—bone cancer	4.12e-05	0.0015	CbGpPWpGaD
Oxybutynin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	4.06e-05	0.00148	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—NT5C3A—bone cancer	3.92e-05	0.00143	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—NDUFA12—bone cancer	3.89e-05	0.00142	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—JUN—bone cancer	3.84e-05	0.0014	CbGpPWpGaD
Oxybutynin—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.83e-05	0.0014	CbGpPWpGaD
Oxybutynin—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.82e-05	0.00139	CbGpPWpGaD
Oxybutynin—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.78e-05	0.00138	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—GRM1—bone cancer	3.78e-05	0.00138	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—IL3—bone cancer	3.74e-05	0.00136	CbGpPWpGaD
Oxybutynin—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.62e-05	0.00132	CbGpPWpGaD
Oxybutynin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.57e-05	0.0013	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—NT5C3A—bone cancer	3.22e-05	0.00117	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—GNA11—bone cancer	3.2e-05	0.00117	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—GNA11—bone cancer	3.19e-05	0.00116	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—SMO—bone cancer	3.17e-05	0.00116	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—SMO—bone cancer	3.16e-05	0.00115	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—GNA11—bone cancer	3.16e-05	0.00115	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—SMO—bone cancer	3.13e-05	0.00114	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—GRM4—bone cancer	3.07e-05	0.00112	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—RGS1—bone cancer	3.07e-05	0.00112	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—GRM4—bone cancer	3.06e-05	0.00112	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—RGS1—bone cancer	3.06e-05	0.00112	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—GRM4—bone cancer	3.03e-05	0.00111	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—RGS1—bone cancer	3.03e-05	0.00111	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—GNA11—bone cancer	2.9e-05	0.00106	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—IL3—bone cancer	2.9e-05	0.00106	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—GNA11—bone cancer	2.89e-05	0.00106	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—IL3—bone cancer	2.89e-05	0.00105	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—GNA11—bone cancer	2.87e-05	0.00105	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—IL3—bone cancer	2.86e-05	0.00104	CbGpPWpGaD
Oxybutynin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.86e-05	0.00104	CbGpPWpGaD
Oxybutynin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.85e-05	0.00104	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—SMO—bone cancer	2.66e-05	0.000971	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—GRM1—bone cancer	2.66e-05	0.000971	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—GRM1—bone cancer	2.65e-05	0.000968	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—IL3—bone cancer	2.63e-05	0.00096	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—GRM1—bone cancer	2.63e-05	0.000958	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—IL3—bone cancer	2.62e-05	0.000957	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—IL3—bone cancer	2.6e-05	0.000948	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—NDUFA12—bone cancer	2.54e-05	0.000926	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—TP53—bone cancer	2.53e-05	0.000923	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—GNA11—bone cancer	2.44e-05	0.000888	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—ENO2—bone cancer	2.36e-05	0.00086	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—ATF1—bone cancer	2.26e-05	0.000826	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—IL3—bone cancer	2.21e-05	0.000805	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—DHFR—bone cancer	2.19e-05	0.000798	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—NT5C3A—bone cancer	2.1e-05	0.000768	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—GNA11—bone cancer	2.04e-05	0.000746	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—ENO2—bone cancer	1.98e-05	0.000723	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—TGFBR2—bone cancer	1.89e-05	0.000689	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—SMO—bone cancer	1.88e-05	0.000684	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—SMO—bone cancer	1.87e-05	0.000682	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—CYP3A4—bone cancer	1.85e-05	0.000676	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—SMO—bone cancer	1.85e-05	0.000675	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—DHFR—bone cancer	1.84e-05	0.000671	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—IGF1R—bone cancer	1.78e-05	0.000648	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—GNA11—bone cancer	1.72e-05	0.000627	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—ENO2—bone cancer	1.72e-05	0.000626	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—GNA11—bone cancer	1.72e-05	0.000626	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—GNA11—bone cancer	1.71e-05	0.000624	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—GNA11—bone cancer	1.69e-05	0.000618	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—ATF1—bone cancer	1.59e-05	0.000582	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—DHFR—bone cancer	1.59e-05	0.000581	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—ATF1—bone cancer	1.59e-05	0.00058	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—GSTP1—bone cancer	1.59e-05	0.000578	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—ATF1—bone cancer	1.57e-05	0.000574	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—CYP3A4—bone cancer	1.56e-05	0.000569	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—IL3—bone cancer	1.56e-05	0.000567	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—IL3—bone cancer	1.55e-05	0.000565	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—IL3—bone cancer	1.54e-05	0.00056	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—GNA11—bone cancer	1.49e-05	0.000543	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—ENO2—bone cancer	1.41e-05	0.000514	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—CYP3A4—bone cancer	1.35e-05	0.000492	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.34e-05	0.00049	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—GSTP1—bone cancer	1.33e-05	0.000486	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—TGFBR2—bone cancer	1.33e-05	0.000485	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—TGFBR2—bone cancer	1.33e-05	0.000484	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—TGFBR2—bone cancer	1.31e-05	0.000479	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—DHFR—bone cancer	1.31e-05	0.000477	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—KIT—bone cancer	1.29e-05	0.00047	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—IGF1R—bone cancer	1.25e-05	0.000456	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—IGF1R—bone cancer	1.25e-05	0.000455	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—IGF1R—bone cancer	1.24e-05	0.00045	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—GNA11—bone cancer	1.22e-05	0.000446	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—BRAF—bone cancer	1.21e-05	0.000442	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—EGFR—bone cancer	1.17e-05	0.000428	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—GSTP1—bone cancer	1.15e-05	0.000421	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—CYP3A4—bone cancer	1.11e-05	0.000404	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—MDM2—bone cancer	1.02e-05	0.00037	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—GSTP1—bone cancer	9.48e-06	0.000346	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—ENO2—bone cancer	9.22e-06	0.000336	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—KIT—bone cancer	9.08e-06	0.000331	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—KIT—bone cancer	9.05e-06	0.00033	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—KIT—bone cancer	8.96e-06	0.000327	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—JUN—bone cancer	8.82e-06	0.000322	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—MMP9—bone cancer	8.59e-06	0.000313	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—DHFR—bone cancer	8.55e-06	0.000312	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—BRAF—bone cancer	8.53e-06	0.000311	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—BRAF—bone cancer	8.5e-06	0.00031	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—BRAF—bone cancer	8.42e-06	0.000307	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—EGFR—bone cancer	8.27e-06	0.000302	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—EGFR—bone cancer	8.24e-06	0.000301	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—PTGS2—bone cancer	8.21e-06	0.0003	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—EGFR—bone cancer	8.16e-06	0.000298	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—GNA11—bone cancer	7.99e-06	0.000292	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—MDM2—bone cancer	7.15e-06	0.000261	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—MDM2—bone cancer	7.13e-06	0.00026	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—MDM2—bone cancer	7.06e-06	0.000257	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—EGFR—bone cancer	6.94e-06	0.000253	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—PTGS2—bone cancer	6.91e-06	0.000252	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—JUN—bone cancer	6.21e-06	0.000227	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—GSTP1—bone cancer	6.2e-06	0.000226	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—JUN—bone cancer	6.19e-06	0.000226	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—JUN—bone cancer	6.13e-06	0.000224	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—MMP9—bone cancer	6.04e-06	0.00022	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—MMP9—bone cancer	6.03e-06	0.00022	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—PTGS2—bone cancer	5.98e-06	0.000218	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—MMP9—bone cancer	5.97e-06	0.000218	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—TP53—bone cancer	5.82e-06	0.000212	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—PTGS2—bone cancer	4.91e-06	0.000179	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—EGFR—bone cancer	4.88e-06	0.000178	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—EGFR—bone cancer	4.87e-06	0.000178	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—EGFR—bone cancer	4.82e-06	0.000176	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—TP53—bone cancer	4.1e-06	0.00015	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—TP53—bone cancer	4.09e-06	0.000149	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—TP53—bone cancer	4.05e-06	0.000148	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—PTGS2—bone cancer	3.21e-06	0.000117	CbGpPWpGaD
